Cargando…

MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses

With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, David, Meyer, Christian T., Graves, Diana, Sen, Rupashree, Fu, Juan, Tran, Emily, Mirza, Bilal, Rodriguez, Gabriel, Lang, Cara, Feng, Hanwen, Quaranta, Vito, Wilson, John T., Kim, Young J., Korrer, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/
https://www.ncbi.nlm.nih.gov/pubmed/36059502
http://dx.doi.org/10.3389/fimmu.2022.936129
_version_ 1784781660605120512
author Taylor, David
Meyer, Christian T.
Graves, Diana
Sen, Rupashree
Fu, Juan
Tran, Emily
Mirza, Bilal
Rodriguez, Gabriel
Lang, Cara
Feng, Hanwen
Quaranta, Vito
Wilson, John T.
Kim, Young J.
Korrer, Michael J.
author_facet Taylor, David
Meyer, Christian T.
Graves, Diana
Sen, Rupashree
Fu, Juan
Tran, Emily
Mirza, Bilal
Rodriguez, Gabriel
Lang, Cara
Feng, Hanwen
Quaranta, Vito
Wilson, John T.
Kim, Young J.
Korrer, Michael J.
author_sort Taylor, David
collection PubMed
description With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple adjuvants are used in combination to bolster further and shape cellular immunity to tumor antigens. However, rigorous quantification of adjuvants’ synergistic interactions is challenging due to partial redundancy in costimulatory molecules and cytokine production, leading to the common assumption that combining both adjuvants at the maximum tolerated dose results in optimal efficacy. Herein, we examine this maximum dose assumption and find combinations of these doses are suboptimal. Instead, we optimized dendritic cell activation by extending the Multidimensional Synergy of Combinations (MuSyC) framework that measures the synergy of efficacy and potency between two vaccine adjuvants. Initially, we performed a preliminary in vitro screening of clinically translatable adjuvant receptor targets (TLR, STING, NLL, and RIG-I). We determined that STING agonist (CDN) plus TLR4 agonist (MPL-A) or TLR7/8 agonist (R848) as the best pairwise combinations for dendritic cell activation. In addition, we found that the combination of R848 and CDN is synergistically efficacious and potent in activating both murine and human antigen-presenting cells (APCs) in vitro. These two selected adjuvants were then used to estimate a MuSyC-dose optimized for in vivo T-cell priming using ovalbumin-based peptide vaccines. Finally, using B16 melanoma and MOC1 head and neck cancer models, MuSyC-dose–based adjuvating of cancer vaccines improved the antitumor response, increased tumor-infiltrating lymphocytes, and induced novel myeloid tumor infiltration changes. Further, the MuSyC-dose–based adjuvants approach did not cause additional weight changes or increased plasma cytokine levels compared to CDN alone. Collectively, our findings offer a proof of principle that our MuSyC-extended approach can be used to optimize cancer vaccine formulations for immunotherapy.
format Online
Article
Text
id pubmed-9437625
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94376252022-09-03 MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses Taylor, David Meyer, Christian T. Graves, Diana Sen, Rupashree Fu, Juan Tran, Emily Mirza, Bilal Rodriguez, Gabriel Lang, Cara Feng, Hanwen Quaranta, Vito Wilson, John T. Kim, Young J. Korrer, Michael J. Front Immunol Immunology With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple adjuvants are used in combination to bolster further and shape cellular immunity to tumor antigens. However, rigorous quantification of adjuvants’ synergistic interactions is challenging due to partial redundancy in costimulatory molecules and cytokine production, leading to the common assumption that combining both adjuvants at the maximum tolerated dose results in optimal efficacy. Herein, we examine this maximum dose assumption and find combinations of these doses are suboptimal. Instead, we optimized dendritic cell activation by extending the Multidimensional Synergy of Combinations (MuSyC) framework that measures the synergy of efficacy and potency between two vaccine adjuvants. Initially, we performed a preliminary in vitro screening of clinically translatable adjuvant receptor targets (TLR, STING, NLL, and RIG-I). We determined that STING agonist (CDN) plus TLR4 agonist (MPL-A) or TLR7/8 agonist (R848) as the best pairwise combinations for dendritic cell activation. In addition, we found that the combination of R848 and CDN is synergistically efficacious and potent in activating both murine and human antigen-presenting cells (APCs) in vitro. These two selected adjuvants were then used to estimate a MuSyC-dose optimized for in vivo T-cell priming using ovalbumin-based peptide vaccines. Finally, using B16 melanoma and MOC1 head and neck cancer models, MuSyC-dose–based adjuvating of cancer vaccines improved the antitumor response, increased tumor-infiltrating lymphocytes, and induced novel myeloid tumor infiltration changes. Further, the MuSyC-dose–based adjuvants approach did not cause additional weight changes or increased plasma cytokine levels compared to CDN alone. Collectively, our findings offer a proof of principle that our MuSyC-extended approach can be used to optimize cancer vaccine formulations for immunotherapy. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9437625/ /pubmed/36059502 http://dx.doi.org/10.3389/fimmu.2022.936129 Text en Copyright © 2022 Taylor, Meyer, Graves, Sen, Fu, Tran, Mirza, Rodriguez, Lang, Feng, Quaranta, Wilson, Kim and Korrer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Taylor, David
Meyer, Christian T.
Graves, Diana
Sen, Rupashree
Fu, Juan
Tran, Emily
Mirza, Bilal
Rodriguez, Gabriel
Lang, Cara
Feng, Hanwen
Quaranta, Vito
Wilson, John T.
Kim, Young J.
Korrer, Michael J.
MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title_full MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title_fullStr MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title_full_unstemmed MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title_short MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses
title_sort musyc dosing of adjuvanted cancer vaccines optimizes antitumor responses
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/
https://www.ncbi.nlm.nih.gov/pubmed/36059502
http://dx.doi.org/10.3389/fimmu.2022.936129
work_keys_str_mv AT taylordavid musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT meyerchristiant musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT gravesdiana musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT senrupashree musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT fujuan musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT tranemily musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT mirzabilal musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT rodriguezgabriel musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT langcara musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT fenghanwen musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT quarantavito musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT wilsonjohnt musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT kimyoungj musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses
AT korrermichaelj musycdosingofadjuvantedcancervaccinesoptimizesantitumorresponses